Advertisement

Der Internist pp 688-696 | Cite as

Therapeutische Prinzipien bei pulmonaler Hypertonie und Cor pulmonale

  • F. V. Kohl
Chapter

Zusammenfassung

Die pulmonale Hypertonie ist die gemeinsame Endstrecke, in die verschiedene pathophysiologische Zustände münden können. Da die morphologisch fixierte pulmonale Hypertonie kausal nicht behandelbar ist, muß auf die Frühdiagnose von disponierenden Erkrankungen besonders Gewicht gelegt werden. Hier liegt der eigentliche therapeutische Ansatzpunkt. Die fixierte pulmonale Hypertonie ist lediglich ausgeklügelten symptomatisch ansetzenden Maßnahmen zugänglich.

Schlüsselwörter

Cor pulmonale Obstruktive Lungenerkrankungen Schlafapnoe Syndrom-Pleuraschwarten Thoraxdeformitäten Alveolo-vaskulärer Reflex 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abraham AS, Cole RB, Green LD (1963) Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studied by serial observation during recovery. Circulation 27:594CrossRefGoogle Scholar
  2. 2.
    Altmann M, Robin ED (1969) Platypnea (diffuse Zone I phenomenon?) N Engl J Med 281:1347CrossRefGoogle Scholar
  3. 3.
    Aviado DM Jr, Schmidt CF (1957) Effects of sympathomimetic drugs on pulmonary circulation, with special reference to a new pulmonary vasodilator. J Pharmacol Exp Ther 120:512PubMedGoogle Scholar
  4. 4.
    Behnke RH, Williams JF, White DH (1963) The effect of acetylcholine infusion upon cardiac dynamics in patients with pulmonary emphysema. Am J Cardiol 10:57Google Scholar
  5. 5.
    Bergofsky EH (1986) Vasodilators in chronic obstructive pulmonary disease. In: Bergofsky EH (ed) Abnormal pulmonary circulation. Livingstone, New York, p 313Google Scholar
  6. 6.
    Brent BN, Berger HJ, Matthay RA, Mahler D, Pytlik L, Zaret BL (1983) Contrasting acute effects of vasodilators (nitroglycerine, nitroprusside and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: A combined radionuclide-hemodynamic study. Am J Cardiol 51:1682PubMedCrossRefGoogle Scholar
  7. 7.
    Brigham KL (1987) Conference summary: lipid mediators in the pulmonary circulation. Am Rev Respir Dis 136:785PubMedCrossRefGoogle Scholar
  8. 8.
    Burghuber OG (1987) Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease. Respiration 52:86PubMedCrossRefGoogle Scholar
  9. 9.
    Charms BL (1961) Primary pulmonary hypertension. Effect of unilateral pulmonary artery occlusion and infusion of acetylcholine. Am J Cardiol 99:94CrossRefGoogle Scholar
  10. 10.
    Corriveau ML, Minh V-D, Dolan GF (1987) Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Med 83:886PubMedCrossRefGoogle Scholar
  11. 11.
    Dalai JJ, Griffiths BE, Henderson AH (1981) Primary pulmonary hypertension: Effects of nifedipine. Br Heart J 46:230CrossRefGoogle Scholar
  12. 12.
    Danahy DT, Tobis JM, Aronow WS, Chetty K, Glauser F (1979) Effects of isosorbide dinitrate on pulmonary hypertension in chronic obstructive pulmonary disease. Clin Pharmacol Ther 25:541PubMedGoogle Scholar
  13. 13.
    Daoud FS, Reeves JT, Kelly DB (1978) Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am J Cardiol 42:817PubMedCrossRefGoogle Scholar
  14. 14.
    Daum S, Goerg R, Schlehe H (1983) Iso-sorbiddinitrat (ISDN) in der Therapie der primären pulmonalen Hypertonie. Prax Klin Pneumol 37:67PubMedGoogle Scholar
  15. 15.
    De Feyter PJ, Kerkkamp HJJ, de Jong JP (1983) Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J 105:333PubMedCrossRefGoogle Scholar
  16. 16.
    Douglas JS (1983) Hemodynamic effects of nifedipine in primary pulmonary hypertension. J Am Coll Cardiol 2:174PubMedCrossRefGoogle Scholar
  17. 17.
    Ferlinz R (1984) Sauerstoffbehandlung bei obstruktiver Lungenerkrankung. Dtsch Med Wochenschr 109:1425PubMedGoogle Scholar
  18. 18.
    Ferrer MI, Enson Y, Kilcoyne M, Harvey RM (1971) Effects of isoproterol on the pulmonary circulation in patients with chronic obstructive lung disease. Circulation 43:528PubMedCrossRefGoogle Scholar
  19. 19.
    Fisher J, Mack RJ, Likier HM, Schiff AN, Borer JS (1987) Nifedipine in pulmonary arterial hypertension. Chest 92:400PubMedCrossRefGoogle Scholar
  20. 20.
    Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 70:580PubMedCrossRefGoogle Scholar
  21. 21.
    Green LH, Smith TW (1977) The use of digitalis in patients with pulmonary disease. Ann Intern Med 87:459PubMedCrossRefGoogle Scholar
  22. 22.
    Grützmacher I, Schicht R, Schlaeger R, Sill V (1984) Hämodynamik des kleinen Kreislaufs bei Patienten mit chronisch obstruktiver Atemwegserkrankung und pulmonaler Hypertonie in Abhängigkeit von den Theophyllinkonzentrationen im Serum. Prax Klin Pneumol 38:19PubMedGoogle Scholar
  23. 23.
    Halpern SM, Shah PK, Lehrman S, Goldberg HS, Jasper AC, Koerner SK (1987) Prostaglandin E1 as a screening vasodilator in primary pulmonary hypertension. Chest 92:686PubMedCrossRefGoogle Scholar
  24. 24.
    Harris P, Heath H (1977) The human pulmonary circulation, 2nd ed. Churchill Livingstone, Edingburgh, p 199Google Scholar
  25. 25.
    Harris P, Segel N, Bishop JM (1968) The relation between pressure and flow in the pulmonary circulation in normal subjects and in patients with chronic bronchitis and mitral stenosis. Cardio-vasc Res 2:73CrossRefGoogle Scholar
  26. 26.
    Harrison BD, Stokes TC (1982) Secondary polycythaemia: its causes, effects and treatment. Br J Dis Chest 76:313PubMedCrossRefGoogle Scholar
  27. 27.
    Heath D, Edwards JE (1958) The pathology of hypertensive pulmonary vascular disease: A description of six grades of structural changes in the pulmonary arteries with special references to congenital cardiac septal defects. Circulation 18:533PubMedCrossRefGoogle Scholar
  28. 28.
    Heath D, Smith P (1979) Pulmonary vascular disease secondary to lung disease. In: Moser KM (ed) Pulmonary vascular diseases. Dekker, New York, p 387Google Scholar
  29. 29.
    Henley DC, Douglas NJ, Lamb D (1980) Nocturnal hypoxemia and long term domiciliary oxygen in blue and bloated bronchitis. Chest 77:305Google Scholar
  30. 30.
    Hermiller JB, Bambach D, Thompson MJ, Huss P, Fontana ME, Magorien RD, Unverferth DV, Leier CV (1982) Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. Ann Intern Med 97:480PubMedCrossRefGoogle Scholar
  31. 31.
    Hoffmann JIE, Rudolph AM, Heymann MA (1981) Pulmonary vascular disease and congenital heart lesions : Pathologic features and causes. Circulation 64:873CrossRefGoogle Scholar
  32. 32.
    Irnell L, Nordgren L (1966) Effects of acetylcholine infusion on the pulmonary circulation in patients with asthma. Acta Med Scand 179:385PubMedCrossRefGoogle Scholar
  33. 33.
    Kadowitz PJ, Hymann AL (1982) Hydralazine and the treatment of primary pulmonary hypertension. N Engl J Med 306:1357PubMedCrossRefGoogle Scholar
  34. 34.
    Kanemoto N, Sasamoto H (1979) Pulmonary hemodynamics in primary pulmonary hypertension. Jpn Heart J 20:395PubMedCrossRefGoogle Scholar
  35. 35.
    Kastanos N, Estopa R, Rodriquez-Roisin R, Agusti-Vidal A (1982) Letter to the editor. N Engl J Med 307:1215Google Scholar
  36. 36.
    Kennedy T, Summer W (1982) Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. Am J Cardiol 50:864PubMedCrossRefGoogle Scholar
  37. 37.
    Klinke WP, Gilbert JAL (1980) Diazoxide in primary pulmonary hypertension. N Engl J Med 302:91PubMedCrossRefGoogle Scholar
  38. 38.
    Kohl FV (1979) Therapie des Cor pulmonale. Physiologische und pathophy-siologische Aspekte. Dtsch Med Wochenschr 19:685CrossRefGoogle Scholar
  39. 39.
    Konietzko N, Schlehe H, Härich B, Matthys H (1975) Effect of isosorbide dinitrate on hemodynamics and respiration of patients with coronary artery disease and of patients with chronic cor pulmonale. Respiration 32:368PubMedCrossRefGoogle Scholar
  40. 40.
    Kronzon I, Cohen M, Winer HE (1982) Adverse effect of hydralazine in patients with primary pulmonary hypertension. JAMA 247:3112PubMedCrossRefGoogle Scholar
  41. 41.
    Lee TD Jr, Roveti GC, Ross RS (1963) The hemodynamic effects of isoproterenol on pulmonary hypertension in man. Am Heart J 65:361PubMedCrossRefGoogle Scholar
  42. 42.
    Leggett RJ, Cooke NJ, Clancy L, Leitch AG, Kirby BJ, Flenley DC (1976) Longterm domiciliary oxygen therapy in cor pulmonale complicating chronic bronchitis and emphysema. Thorax 31:414PubMedCrossRefGoogle Scholar
  43. 43.
    Marshall RJ, Helmholz F, Shepherd JT (1959) Effect of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension. Circulation 20:391PubMedCrossRefGoogle Scholar
  44. 44.
    Mathur PN, Powles ACP, Pugsley SO, McEwan MP, Campbell EJ (1981) Effect of digoxin on right ventricular funktion in severe chronic airflow obstruction. Ann Intern Med 95:283PubMedCrossRefGoogle Scholar
  45. 45.
    McLeod AA, Wise JR, Daly K, Jewitt D (1981) Nifedipine in treatment of primary pulmonary hypertension. Br Heart J 45:619Google Scholar
  46. 46.
    McMurtry IF, Davidson AB, Reeves JT, Grover RF (1976) Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonist in isolated rat lungs. Circ Res 38:99PubMedCrossRefGoogle Scholar
  47. 47.
    Medical Research Council Working Party (1981) Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet I:681Google Scholar
  48. 48.
    Meyrick B, Perkett EA, Brigham KL (1987) Inflammation and models of chronic pulmonary hypertension. Am Rev Respir Dis 136:765PubMedCrossRefGoogle Scholar
  49. 49.
    Morrison DA (1987) Pulmonary hypertension in chronic obstructive pulmonary disease: The right ventricular hypothesis (editorial). Chest 92:387PubMedCrossRefGoogle Scholar
  50. 50.
    Morrison D, Caldwell J, Lakshminaryan S, Ritchie JL, Kennedy JW (1983) The acute effects of low flow oxygen and iso-sorbide dinitrate on left and right ventricular ejection fractions in chronic obstructive pulmonary disease. J Am Coll Cardiol 2:652PubMedCrossRefGoogle Scholar
  51. 51.
    Naeije R, Melot C, Mols P, Hallemans R (1982) Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 125:1PubMedGoogle Scholar
  52. 52.
    Nagasaka Y, Akutsu H, Lee YS, Fujimoto S, Chikamori J (1978) Longterm favorable effect of oxygen administration in a patient with primary pulmonary hypertension. Chest 74:299PubMedCrossRefGoogle Scholar
  53. 53.
    NOTT Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 93:391CrossRefGoogle Scholar
  54. 54.
    Packer M, Greenberg B, Massie B, Dash H (1982) Deleterious effects of hydralazine in patients with primary pulmonary hypertension. N Engl J Med 306:1326PubMedCrossRefGoogle Scholar
  55. 55.
    Packer M, Medina N, Yushak M (1983) Adverse hemodynamic and clinical effects of nifedipine in patients with primary pulmonary hypertension. J Am Coll Cardiol 1:736Google Scholar
  56. 56.
    Parker JO, Ashekian PB, DiGeorge S, West RO (1967) Hemodynamic effects of aminophylline in chronic obstructive pulmonary disease. Circulation 35:365PubMedCrossRefGoogle Scholar
  57. 57.
    Pearl RG, Rosenthal MH, Schroeder JJ, Ashton JPA (1983) Acute hemodynamic effects of nitroglycerine in pulmonary hypertension. Ann Intern Med 99:9PubMedCrossRefGoogle Scholar
  58. 58.
    Podszus T, Becker I (1987) The prevalence of increased pulmonary arterial pressure among sleep apneics. In: Peter JH, Podszus T, v Wichert P (eds) Sleep related disorders and internal diseases. Springer, Berlin Heidelberg New York, p 241CrossRefGoogle Scholar
  59. 59.
    Pontzer VM (1974) Beobachtungen über die Wirkung von Theophyllinäthylen-diamin auf den Pulmonalarteriendruck bei Patienten mit chronischem Cor pulmonale. Drug Res 24:947Google Scholar
  60. 60.
    Rabinovitch M (1987) Prostaglandins and structural changes in pulmonary arteries. Am Rev Respir Dis 136:777PubMedCrossRefGoogle Scholar
  61. 61.
    Rao BNS, Moller JH, Edwards JE (1969) Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation 40:583CrossRefGoogle Scholar
  62. 62.
    Replogle RL, Meiselmann HJ, Merrill EW (1967) Clinical implications of blood rheology studies. Circulation 36:148PubMedCrossRefGoogle Scholar
  63. 63.
    Rich S, Brundage BH, Levy PS (1985) The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 71:1191PubMedCrossRefGoogle Scholar
  64. 64.
    Rich S, Brundage BH (1986) The pharmacologic treatment of primary pulmonary hypertension In: Bergofsky EH (ed) Abnormal pulmonary circulation. Livingstone, New York, p 283Google Scholar
  65. 65.
    Rich S, Ganz R, Levy PS (1983) Comparative effects of hydralazine, nifedipine, and amrinone in primary pulmonary hypertension. Am J Cardiol 52:1104PubMedCrossRefGoogle Scholar
  66. 66.
    Rich S, Levy PS (1984) Characteristics of surviving and non-surviving patients with primary pulmonary hypertension. Am J Med 76:573PubMedCrossRefGoogle Scholar
  67. 67.
    Rich S, Martinez J, Lam W, Rosen KM (1982) Captopril as therapy for patients with pulmonary hypertension : The problem of variability in assessing chronic drug therapy. Br Heart J 48:272PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Rich S, Martinez J, Lam W, Levy PS, Rosen KM (1983) Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension : Guidelines for determining a pulmonary vasodilator response. Am Heart J 105:119PubMedCrossRefGoogle Scholar
  69. 69.
    Roth RA, Ganey PE (1987) Arachidonic acid metabolites and the mechanisms of monocrotaline pneumotoxicity. Am Rev Respir Dis 136:762PubMedCrossRefGoogle Scholar
  70. 70.
    Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66:334PubMedCrossRefGoogle Scholar
  71. 71.
    Rubin LF, Peter RH (1980) Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 302:69PubMedCrossRefGoogle Scholar
  72. 72.
    Saadjian A, Philip-Joet F, Guintoli A, Torresani J, Arnaud A (1985) Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease. Eur J Respir Dis 67:346PubMedGoogle Scholar
  73. 73.
    Saito D, Haraoka S, Yoshida H, Kusachi S, Yasuhara K, Nishihara M, Fukuhara J, Hagashima H (1983) Primary pulmonary hypertension improved by long-term oral administration of nifedipine. Am Heart J 105:1041PubMedCrossRefGoogle Scholar
  74. 74.
    Samet P, Bernstein WH (1963) Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension. Am Heart J 66:197PubMedCrossRefGoogle Scholar
  75. 75.
    Samet P, Bernstein WH, Widrich J (1966) Intracardiac infusion of acetylcholine in primary pulmonary hypertension. Am Heart J 60:433CrossRefGoogle Scholar
  76. 76.
    Sclavo M, Bucca C, Rolla G, Borello G, Balbi L, Angelino PF (1981) Ipertensione polmonare nella broncopulmopatia cronica ostrutiva. G Ital Cardiol 11:634PubMedGoogle Scholar
  77. 77.
    Shettigar UR, Hultgren HN, Specter M, Martin R, Davies DH (1976) Primary pulmonary hypertension, favorable effect of isoproterenol. N Engl J Med 295:1414PubMedCrossRefGoogle Scholar
  78. 78.
    Siemon VG, Thoma R (1978) Die Wirkung eines Kombinationspräparates aus Fominoben und Oxyäthyltheophyllin auf Lungenfunktion und pulmonale Hämodynamik bei chronisch obstruktiven Atemwegserkrankungen. Arzneimittelforsch 28:698PubMedGoogle Scholar
  79. 79.
    Sill V, Wichert P v (1973) Pulmonale Hypertonie bei Lungenerkrankungen. Internist (Berlin) 14:454Google Scholar
  80. 80.
    Simoneau G, Escourrow P, Duroux P, Lockhart A (1981) Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 304:1582CrossRefGoogle Scholar
  81. 81.
    Schüren KP, Huttleman V, Ramdohr B, Lohmann FW (1972) Lungenkreislauf und kontraktile Funktion des rechten Ventrikels bei chronischem Cor pulmonale. Vergleichende Untersuchungen über den Einfluß von Aminophyllin und Heptaminal. Klin Wochenschr 50:101PubMedCrossRefGoogle Scholar
  82. 82.
    Schüren KP, Macha HN (1978) Isosorbiddinitrat bei chronischem Cor pulmonale. Dtsch Med Wochenschr 103:777PubMedCrossRefGoogle Scholar
  83. 83.
    Stark RD, Finnegan P, Bishop JM (1972) Daily requirements of oxygen to reverse pulmonary hypertension in patients with chronic bronchitis. Br Med J 3:724PubMedCentralPubMedCrossRefGoogle Scholar
  84. 84.
    Swigart RH (1965) Polycythemia and right ventricular hypertrophy. Circ Res 17:30PubMedCrossRefGoogle Scholar
  85. 85.
    Sylvester JT, Gottlieb JE, Rock P, Wetzel RC (1986) Akute hypoxic responses In: Bergofsky EH (ed) Abnormal pulmonary circulation. Livingstone, New York, p 127Google Scholar
  86. 86.
    Timms RM, Khaja FU, Williams GW and the Nocturnal Oxygen Therapy Trial Group (1985) Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 102:29PubMedCrossRefGoogle Scholar
  87. 87.
    Waagenvoort CA, Waagenvoort N (1970) Primary pulmonary hypertension. A pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42:1163CrossRefGoogle Scholar
  88. 88.
    Watkins WD, Peterson MB, Crone RK, Shannon DC, Levine L (1980) Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lance I:1083CrossRefGoogle Scholar
  89. 89.
    Walker AL, Rubin LJ (1987) Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis 136:773CrossRefGoogle Scholar
  90. 90.
    West JB, Dollery CT (1960) Distribution of blood flow and ventilation-perfusion ratio in the lung, measured with radioactive CO2. J Appl Physiol 15:405PubMedGoogle Scholar
  91. 91.
    Widimsky J (1981) Restriktive Form der präkapillären pulmonalen Hypertonie In: Schulz W (Hrsg) Pulmonale Hypertonie. Bücherei des Pneumologen, Bd 6. Thieme, Stuttgart, p 194Google Scholar
  92. 92.
    Wise JR (1983) Nifedipine in the treatment of primary pulmonary hypertension. Am Heart J 105:693PubMedCrossRefGoogle Scholar
  93. 93.
    World Health Organisation (1963) Technical report, Ser 213: Chronic cor pulmonale. Circulation 27:594CrossRefGoogle Scholar
  94. 94.
    Virmani R, Roberts WC (1979) Pulmonary arteries in congenital heart disease : A structure-function analysis. Cardio-vasc Clin 10:445Google Scholar
  95. 95.
    Voelkel NF (1986) Mechanisms of hypoxic pulmonary vasoconstriction. Am Rev Respir Dis 133:1186PubMedGoogle Scholar
  96. 96.
    Voelkel N, Reeves JT (1979) Primary pulmonary hypertension. In : Moser KM (ed) Pulmonary vascular diseases. Dekker, New York, p 573Google Scholar
  97. 97.
    Vogel JH, Weaver WF, Rou RL, Blount SGJ, Grover RF (1962) Pulmonary hypertension on exertion in normal man living lO, 150 feet. Med Thorac 19:269Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • F. V. Kohl
    • 1
  1. 1.Medizinische Universitäts-PoliklinikKlinikum der Philipps-Universität MarburgMarburgDeutschland

Personalised recommendations